Delivery Order SPE2DB20D1050-SPE2DB25FH80K
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count) with a ceiling value of $3,977.47. This contract represents a firm fixed-price delivery order under a competitive, non-set-aside procurement and is scheduled for completion by July 25, 2025. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate office and serves...
- The Defense Logistics Agency awarded a $25,044.82 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units). This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate headquarters...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units) with a contract ceiling value of $7,553.60. This is a firm fixed-price delivery order with no set-aside designation, utilizing open and competitive procurement procedures. The contract is set to complete by August 1, 2025, and represents a direct fulfillment of pharmaceutical supply needs through AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a delivery order valued at $1,923.12 to AmerisourceBergen Drug Corp for Myrbetriq ER 25 mg tablets (90-count supply) on July 28, 2025, with an ultimate completion date of July 29, 2025. This is a firm fixed price contract with no set-aside designation, competitively awarded through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,729.22 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (30-count supply). This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 1, 2025, and represents a competitively awarded transaction under AmerisourceBergen's broader pharmaceutical supply relationships with the federal government. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units) with a ceiling value of $43,359.95. This firm fixed-price delivery order, which is scheduled for completion by August 8, 2025, represents a non-competitive set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count) with a ceiling value of $30,440.85. This firm fixed-price delivery order, which is a child contract under a larger vehicle, reflects no set-aside designation and represents a competitively awarded transaction. The order will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $29,045.67 to AmerisourceBergen Drug Corp for Myrbetriq ER 50 mg tablets (90-count supply) on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a primary...
- The Defense Logistics Agency awarded a delivery order valued at $34,374.97 to AmerisourceBergen Drug Corp for Myrbetriq ER 50 mg tablets (90-count units) on August 5, 2025, with completion targeted for August 6, 2025. This firm fixed price, non-set-aside contract represents a routine pharmaceutical procurement executed under competitive procedures. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical supplier for federal...
- The Defense Logistics Agency awarded a $7,089.10 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units). This is a non-set-aside contract performed at the vendor's location in Conshohocken, Pennsylvania, with an ultimate completion date of July 24, 2025. The delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million...
- SPE2DB20D1050Indefinite Delivery Contract
- SPE2DB20D1050-SPE2DB25FH80KDelivery Order
The Defense Logistics Agency awarded a $7,794.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count unit). The contract utilizes firm fixed-price pricing with an ultimate completion date of July 29, 2025, and represents a non-competitive, non-set-aside award. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $1 billion through December 2026, which serves as the comprehensive vehicle for pharmaceutical and medical supply procurement to support military healthcare systems globally. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor providing critical medical procurement support to federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard. The company's extensive portfolio encompasses brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. This delivery order for Myrbetriq, a medication used to treat overactive bladder, exemplifies the company's role as a prime vendor for routine pharmaceutical fulfillment within the DLA's medical supply chain supporting military and veteran healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.8k | 7/28/25 |